<DOC>
	<DOCNO>NCT01804413</DOCNO>
	<brief_summary>Hypothesis : Pegvisomant combine glucagon stimulation test ( GST ) improve accuracy test use diagnose adult GH cortisol ( steroid hormone ) insufficiency . Study aim : Diagnosing GH cortisol deficiency adult require special test . At present , insulin tolerance test ( ITT ) consider test choice . However , test difficult perform involve give insulin vein decrease blood sugar low level , unpleasant , perform elderly adult history heart disease , seizure disorder stroke . For reason urgent need alternative reliable test . At present , GST consider alternative test ITT accuracy obese patient diabetes remains unclear . Pegvisomant medication increase GH production body . The purpose study find combine pegvisomant GST help improve accuracy test comparable ITT diagnose adult GH cortisol insufficiency . Study design : Subjects recruit Oregon Health &amp; Science University Dynamic Endocrine Testing Unit . A write informed consent obtain screen interview carry . During screen interview , study explain subject detail . For woman child-bearing age , pregnancy test perform . The subject take part three study separate day : ( 1 ) GST ; ( 2 ) pegvisomant ( 1 mg/kg ) injection abdomen 3 day glucagon stimulation test ( ii ) insulin tolerance test . For GST , glucagon inject muscle blood draw perform every 30 min 240 min . For insulin tolerance test , blood draw perform insulin give vein follow blood draw every 15 min 120 min . The data three study analyze study peak growth hormone cortisol level three test compare . A questionnaire use end study subject rank level preference three test . The data study analyze use computer statistical program identity subject cod maintain confidentiality .</brief_summary>
	<brief_title>Pegvisomant With Glucagon Test Assess Adult Growth Hormone Deficiency</brief_title>
	<detailed_description>Background : The diagnosis GH deficiency adult establish provocative test GH secretion . The insulin tolerance test ( ITT ) widely regard gold standard test diagnose adult GH deficiency despite concern practicality , safety , reproducibility , contraindication elderly adult , adult seizures patient ischemic heart disease . The glucagon stimulation test ( GST ) propose alternative ITT follow reason : 1 ) availability ; 2 ) low cost 3 ) safety . This test validate past reliable test assess GH reserve adult child . In addition , number study also show GST capable stimulating GH also ACTH release . However , accuracy reliability GST assess hypothalamic-pituitary-adrenal ( HPA ) axis GH reserve obese diabetic patient still lack . Pegvisomant ( PV ) ( SomavertÂ® ) GH receptor antagonist currently license FDA treatment acromegaly . Physiological study demonstrate acute high dose administration PV enhance endogenous GH stimulation . These data recently utilize Radetti et al . prime L-DOPA test assess reliability diagnostic work GH deficiency short child . Using PV dose 1 mg/kg prime L-DOPA test 21 short child , investigator demonstrate improvement reliability L-DOPA stimulation test diagnose GH deficiency 10 18 ( 56 % ) child initially fail L-DOPA test successfully pass L-DOPA test follow PV-priming . These investigator postulate PV-priming unmasked potentially false diagnosis GH deficiency exploit acute IGF-lowering effect reduce negative feedback GH hypothalamus . We therefore propose proof-of-concept pilot study investigate potential acute GH receptor blockade use PV reduce false positive rate adult undergo GH test GST . In addition , plan investigate effect PV IGF-I bioactivity , measure IGF-I kinase receptor activation ( KIRA ) assay ( 30 ) . Subjects : Ten subject suspect pituitary disease invite participate study . Subjects screen eligibility enrollment study . Intervention : After complete GST , eligible subject randomize undergo either PV-GST ITT . Subjects randomize undergo PV-GST first undergo ITT , vice versa , 4-6 week later . For PV-GST , blood test serum IGF-I IGF-I KIRA level measure patient receive PV dose 1 mg/kg inject subcutaneously . The patient return 3 day ' time undergo GST . For part test , subject receive glucagon administer intramuscularly dose 1 mg subject weigh 90 kg less 1.5 mg subject weigh 90 kg . Measurements : Blood sample measurement glucose , IGF-I , IGF-I KIRA , GH cortisol perform various time-points GST , PV-GST ITT Specific Aims : Primary aim : 1 ) To investigate potential acute GH receptor blockade prim PV glucagon ( PV-GST test ) characteristic peak GH cortisol level ; 2 ) To ascertain cut-point level GH cortisol PV-GST comparison ITT define GH cortisol deficiency . Secondary aim : 1 ) Correlation peak GH cortisol level induce PV-GST BMI ; 2 ) Correlation peak GH cortisol level induce PV-GST fast blood glucose level ; 3 ) Effects PV IGF-I bioactivity determine IGF-I KIRA .</detailed_description>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study . Age 21 55 year Body weight 60 120 kg inclusive Stable weight diet least 3 month prior study entry Poor IV access Known hypersensitivity glucagon Inability unwillingness comply study procedure Clinically significant cardiovascular cerebrovascular disease Current active malignancy nonmelanoma skin cancer Active acromegaly Cushing 's disease Pheochromocytoma Pregnancy Renal failure ( serum creatinine &gt; 2 mg/dl ) Severe acute illness Uncontrolled hypertension ( BP &gt; 160/100 mmHg ) Emotional/social instability likely prejudice study completion Recurrent severe unexplained hypoglycemia Known suspect drug/alcohol abuse Patients history coronary artery disease , cerebrovascular disease , congestive heart failure , arrhythmias seizure disorder would exclude ITT arm regardless age Participation another simultaneous medical investigation trial</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Pegvisomant</keyword>
	<keyword>Growth hormone</keyword>
	<keyword>Cortisol</keyword>
	<keyword>Glucagon</keyword>
	<keyword>Insulin</keyword>
</DOC>